- Meeting abstract
- Open Access
PW03-013 - Behçet's disease: genotype-phenotype correlations
© Takeuchi et al; licensee BioMed Central Ltd. 2013
- Published: 8 November 2013
- Risk Allele
- IL10 mRNA
- IL10 mRNA Expression
Although the therapy for Behçet's disease (BD) has improved since infliximab was approved for refractory retinochoroiditis therapy in Japan, the exact pathogenesis of BD remains unclear. Our recent genome-wide association study has identified the IL10 and IL23R-IL12RB2 loci as susceptibility genes for BD, in addition to HLA-A*26 and B*51. rs1495965 is located in the intergenic region between IL23R and IL12RB2 and rs1800872 is located in the promoter region of IL10. IL-10 is an anti-inflammatory cytokine that may have multiple effects in immunoregulation and inflammation. It is thought that regulatory T cell function related to IL-10 is an important factor in the disease pathogenesis.
To examine the association of IL23R-IL12RB2 and IL10 gene polymorphisms and HLA typing with clinical presentation of BD, and to examine the expression levels of IL10 mRNA, IL23R mRNA, and IL12RB2 mRNA from PBMCs from each genotype in healthy controls.
A total of 464 patients with BD enrolled in our recent genome-wide association study were investigated for association between clinical manifestations and 4 susceptibility loci, rs1495965, rs1800872, HLA-A*26, and HLA-B*51. In our cohort, 196 patients had complete BD and 268 patients had incomplete BD. The expression levels of IL10 mRNA, IL23R mRNA, and IL12RB2 mRNA were examined in 33 healthy controls by real-time PCR.
The frequency of complete BD was significantly increased in patients with the risk allele of rs1800872 under genotypic and recessive models (p=0.0004, 0.0003, respectively). The frequency of skin lesions, ocular lesions, and genital ulcers was also increased in patients homozygous for the risk allele of rs1800872 (p=0.02, 0.05, 0.05, respectively). HLA-A*26, HLA-B*51, and the rs1495965 risk allele showed no association with the frequencies of complete or incomplete BD or specific clinical findings. The frequency of patients with refractory chorioretinal uveitis treated with infliximab was significantly increased among the risk allele carriers of rs1495695 and rs1800872 (p=0.01, 0.02, respectively). The expression level of IL10 mRNA was significantly decreased in the homozygotes for the rs1800872 risk allele. There were no significant differences in the expression levels of IL23R mRNA and IL12RB2 mRNA among rs1495695 risk allele carriers.
This study suggests that the IL10 polymorphism associates with complete BD and the IL23R-IL12RB2 and IL10 gene polymorphisms associate with the severity of uveitis. The latter association may be due to regulation of IL10 mRNA expression.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.